Clinical trials: HPV InfectioN
Human Papilloma Virus Infection
Developing Methods to Investigate Additional Opportunities of HPV Vaccination by Using First-void Urine Samples
The main objective of this study is to develop protocols using FV urine that investigate in vitro whether infectious virions can be neutralized by HPV vaccination.
- Trial name
- HPV-VACPLUS (NCT04391647)
- Testing
- First-void urine collection, Blood draw
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
Cervical Cancer, Vulvar Cancer
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccine in Chinese healthy females 20 to 45 years of age.
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT04425291
- Testing
- 4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL®
- Where
- China
- Volunteers
- 1,680 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Head and Neck Cancer, Squamous Cell Carcinoma
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
The NeoScorch HN study is a single institution multisite phase II trial including 3 cohorts of 25 patients each for patients with newly diagnosed locoregionally advanced, histologically confirmed, head and neck cancer eligible…
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharyngeal Cancer
- Trial name
- (NeoScorch HN) (NCT07209189)
- Testing
- Toripalimab + Chemotherapy, Toripalimab, Chemoradiotherapy or radiation
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Decision Aid, Hpv
Patient Decision Aid Tool for HPV Vaccination Among Adults Ages 27-45 Years Old
The goal of this study is to learn if a patient decision tool for HPV vaccination works for decision-making among adults ages 27-45.
- Trial name
- HPV Decide (NCT06435338)
- Testing
- Patient decision aid, Control
- Where
- United States
- Volunteers
- 632 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Cervical Intraepithelial Neoplasia, Papillomavirus Infections
Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)
High-grade squamous intraepithelial lesions (HSIL), encompassing cervical intraepithelial neoplasia grade 2 (CIN2) with p16 positivity and grade 3 (CIN3), are precancerous conditions that require effective intervention.
- Trial name
- Aurora (NCT07669363)
- Testing
- Loop Electrosurgical Excision Procedure (LEEP) or Cold Knife Conization (CKC), HAL 5% with illumination
- Where
- 28 sites in China
- Volunteers
- 230 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cervical Intraepithelial Neoplasia, Cervical Cancer
Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine
This is a Phase III clinical trial of the novel recombinant HPV 16/18 bivalent vaccine manufactured by Xiamen Innovax Biotech CO., LTD.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT01735006
- Testing
- HPV Vaccine, HEV vaccine
- Where
- China
- Volunteers
- 7,372 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Cervical Cancer, Genital Wart
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 18-45…
- Conditions
- Cervical Cancer, Genital Wart, CIN1, CIN2
- Trial name
- NCT05584332
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)
- Where
- China
- Volunteers
- 3,131 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
N/A - Healthy Subjects
Engaging College Students in Developing and Testing a Video-based Intervention for HPV Vaccination Promotion
HPV vaccines offer hope against HPV-associated cancers for males and females; however, the rate of vaccination has not reached projected public health goals.
- Trial name
- HPV videos (NCT06397378)
- Testing
- short videos related to HPV and the HPV vaccine, CDC HPV Fact Sheet
- Where
- United States
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Michigan State University
Recurrent Condyloma, Nonrecurrent Condyloma
Recurrent and Nonrecurrent Condyloma Treatment
Treatment is considered successful if the difference in the response in the reduction of the affected area is above 30% for any of the doses compared to placebo Patients will be randomised to 1 of 3 treatment arms 1. Placebo 2.
- Trial name
- NCT01639638
- Testing
- PROAPOPTOTIC PEPTIDE CIGB 300
- Where
- Argentina
- Volunteers
- 132 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Human Papillomavirus, Uterine Cervical Neoplasms
An HPV Vaccine Provider Intervention in Safety Net Clinics
The purpose of this study is to develop, deliver and evaluate a provider intervention for mothers and their children to encourage receipt of the human papillomavirus (HPV) vaccine in the children and appropriate cervical cancer…
- Trial name
- NCT02808832
- Testing
- Educational materials
- Where
- United States
- Volunteers
- 806 people, healthy volunteers welcome
- Sponsor
- Meharry Medical College
Human Papilloma Virus Infection
Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHER™ System
The objective is to establish that APTIMA HPV Assay performance on the PANTHER System is comparable to performance on the TIGRIS System.
- Trial name
- NCT01446198
- Where
- 3 sites in United States
- Volunteers
- 11,816 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx
Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
The goal of this clinical research study is to learn if utomilumab, when given with ISA101b, is able to shrink or slow the growth of tumors in patients with incurable HPV+ oropharyngeal squamous cell carcinoma.
- Conditions
- Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer
- Trial name
- NCT03258008
- Testing
- Utomilumab, ISA101b
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
HPV Infection, CIN1
Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions
A Phase 1b/2 multi-centre study evaluating the safety, efficacy and immunogenicity of prime-boost vaccines ChAdOx1-HPV and MVA-HPV in women with HPV related low grade cervical lesions.
- Trial name
- NCT04607850
- Testing
- ChAdOx1-HPV, MVA-HPV
- Where
- 16 sites in Belgium, Estonia and 1 more
- Volunteers
- 108 people
- Sponsor
- Barinthus Biotherapeutics
Cervical Cancer, Human Papillomavirus (HPV) Infection
Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India
Cervical cancer (CC) remains one of the most common malignancies among women in India, with nearly 100,000 women diagnosed annually and over 60,000 preventable deaths annually.
- Conditions
- Cervical Cancer, Human Papillomavirus (HPV) Infection, Human Immunodeficiency Virus (HIV) Infection
- Trial name
- SAKHI (NCT07209917)
- Testing
- SAKHI HPV Intervention, Enhanced Standard of Care (SOC+)
- Where
- 4 sites in India
- Volunteers
- 348 people
- Sponsor
- University of California, Irvine
Cervical Intraepithelial Neoplasia, HPV Infection
Effect of HPV Integration on Prognosis of Young Women With CIN2 in China
Clinically, cervical precancerous lesion is one of the important diseases that endanger the life safety and fertility of young women.
- Conditions
- Cervical Intraepithelial Neoplasia, HPV Infection, Virus Integration, HSIL, High Grade Squamous Intraepithelial Lesions
- Trial name
- NCT05282095
- Testing
- Follow up
- Where
- 20 sites in China
- Volunteers
- 300 people
- Sponsor
- Fujian Maternity and Child Health Hospital
Human Papillomavirus Infection
Efficacy of Probiotic Lactobacillus Crispatus M247 in Promoting High-risk Human Papillomavirus (HR-HPV) Infection Clearance and Modifying Vaginal Microbiota
This clinical trial evaluates the efficacy of the probiotic strain Lactobacillus crispatus M247 in promoting the clearance of genital high-risk human papillomavirus (HR-HPV) infection and restoring the balance of the vaginal…
- Trial name
- NCT06802809
- Testing
- Lactobacillus crispatus M247 (Crispact®)
- Where
- 3 sites in Italy
- Volunteers
- 66 people
- Sponsor
- Liaquat University of Medical & Health Sciences
Infections, Papillomavirus
Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00456807
- Testing
- Cervarix TM
- Where
- 2 sites in Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancers, Vulvar Cancer
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
To evaluate the safety and immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years.
- Conditions
- Cervical Cancers, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT03676101
- Testing
- 9-valent HPV Recombinant Vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Vulvar Intraepithelial Neoplasia, Genital Warts
SR-T100 Gel Efficacy & Safety Study for Vulva Pre-cancerous Lesions & Cutaneous Condyloma
This pilot clinical study is to evaluate the efficacy \& safety of SR-T100 gel (2.3% of SM in Solanum undatum plant extract) in patients with VIN(s) or EGW(s).
- Trial name
- NCT01676792
- Testing
- SR-T100 gel with 2.3% of SM in Solanum undatum plant extract
- Where
- Taiwan
- Volunteers
- 29 people
- Sponsor
- National Cheng-Kung University Hospital
Cervical Cancer, CIN2
Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV
The purpose of this study is to explore whether an anti-cancer medication (5-fluorouracil cream) placed in the vagina after a surgical excision procedure is an acceptable and useful form of treatment for cervical precancer among…
- Conditions
- Cervical Cancer, CIN2, CIN3, Human Immunodeficiency Virus
- Trial name
- ACT 2 (NCT05413811)
- Testing
- 5 Fluorouracil (5 FU) Cream
- Where
- South Africa
- Volunteers
- 180 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center